Ukraine will receive the vaccine produced by the Sinovac Biotech Chinese company within 30 days after registration, Health Minister of Ukraine Maksym Stepanov said during a press briefing in Kyiv on Thursday.
“Due to the supply of the vaccine from Sinovac Biotech, we will receive 1.913 million doses of vaccine against coronavirus disease. During the first delivery, some 700,000 doses will arrive in Ukraine, we will receive them within 30 days after the vaccine is registered either in the manufacturing country or in other countries (the United States, UK, EU, Brazil, etc.),” he said.
“The company is to release the results of clinical trials in Brazil on January 7. It is stipulated that the vaccine must have an efficiency of at least 70%. Negotiations with the manufacturer have lasted since September 2020. The agreement was signed by the Lekhim Ukrainian pharmaceutical company,” the minister said.
According to Stepanov, the third phase of clinical trials was done in Brazil (13,060 patients), Indonesia (1,600 patients) and Turkey (1,325 patients). The efficiency in Indonesia was 97%, in Turkey it was 91%. The FDA recommends that COVID-19 vaccines should be more than 50% effective.
The minister said that all vaccines purchased for government funds will be free for all citizens of Ukraine.
In addition, the head of the Health Ministry said that the department is at the final stage of signing contracts with other vaccine manufacturing companies, and also intends to increase the number of vaccines that will be supplied to Ukraine as part of the COVAX initiative.
Minister of Health of Ukraine Maksym Stepanov has held talks with Executive Director for International and Government Affairs of AstraZeneca Alec van Gelder on the timing and logistics of deliveries of the COVID-19 vaccine to Ukraine.
“For several months, the Ministry of Health of Ukraine has been establishing active and effective communication with the head office of AstraZeneca. Today we have already discussed the logistics and delivery terms of vaccines against COVID-19 from AstraZeneca in Ukraine. Our state is completely ready to receive vaccines. A plan for vaccination of the population has been fully developed,” Stepanov said, the press service of the Ministry of Health of Ukraine reported on Facebook.
Alec van Gelder, in turn, noted readiness for active cooperation with Ukraine.
“We thank the Ministry of Health of Ukraine for consistency and openness. Now we will process options for the supply of vaccines in Ukraine in the near future,” he summed up.
It is noted that on December 30, the Oxford-AstraZeneca vaccine was approved for use in the UK, vaccination will begin on Monday.
As reported, the Ministry of Health of Ukraine signed a contract for the supply of vaccines against COVID-19 produced by the Chinese company Sinovac Biotech to Ukraine.
More than 70% of beds allocated for patients with COVID-19 are provided with oxygen today in Ukraine, Deputy Minister of Health, Chief Sanitary Doctor of Ukraine Viktor Liashko said.
“Today, more than 70% of all beds allocated for COVID-19 are provided with oxygen. Now 55-60% of those hospitalized need oxygen treatment,” Liashko wrote on his Facebook page.
He said that 64,349 beds have been redesigned in hospitals to provide medical care for people with COVID-19, of which 44,436 are oxygen beds, which is almost 70% of all allocated beds.
“Today in hospitals we have 29,487 free beds with oxygen. On average, 55-60% of those hospitalized with COVID-19 need oxygen support,” he said.
The neighboring countries of Ukraine, in addition to Poland, Belarus and the Russian Federation, are in the “red” zone for COVID-19, according to data published on the website of the Ministry of Health as of December 24.
The “red” zone includes countries with an incidence rate per 100,000 population over the past 14 days higher than in Ukraine (374). There are 45 countries in total.
Of the closest neighbors of Ukraine, the “red” zone includes Slovakia (634,900 cases of COVID-19 per 100,000 population), Moldova (460,400), Romania (400,300) and Hungary (521,700).
Lithuania, Georgia, Slovenia, U.S., Montenegro, Sweden, the Netherlands, Czech Republic, Switzerland, Great Britain, Turkey, Austria, Germany are also among the countries of the “red” zone.
The list of countries of the “green” zone includes, in particular, Italy, Israel, Belgium, France, Canada, Spain, Greece, Japan, India, and Egypt.
Of the closest neighbors of Ukraine, the “green” zone includes Belarus (279 cases per 100,000 of the population), the Russian Federation (206,900) and Poland (366,700).
The test systems that are used in Ukraine can detect a mutated strain of coronavirus, which was recorded in the UK, Ukrainian Health Minister Maksym Stepanov told reporters on Thursday.
“The complexity of the situation with the mutated strain of coronavirus in the UK is that, according to preliminary data, it is 70% more infectious. At the same time, they have no evidence that it causes more complications, more severe disease or increased mortality. We increased control. Our test systems are able to detect this strain,” he said.
The minister noted that no cases of the mutated strain of coronavirus have been registered in Ukraine yet.
“We have a small number of flights from the UK. Basically, our citizens, who work there or study, come. We do not consider it necessary to close air traffic and then send planes to pick up our citizens,” Stepanov added.
Pharmaceutical manufacturers have overcome the logistics problems that arose at the beginning of the COVID-19 pandemic and the shortage of certain active pharmaceutical ingredients (APIs), said President of the Association of Manufacturers of Medications of Ukraine (AMMU) Petro Bahriy.
“Among the general problems that have arisen with the introduction of quarantine [at the beginning of the epidemic], I would single out the problems of logistics, difficulties with the import, transportation of pharmaceutical products and their registration in connection with closed borders, as well as problems with the so-called ‘anticovid’ goods, for which there is an increased demand today,” he said in an exclusive interview with Interfax-Ukraine.
Bahriy noted that the price of some APIs of drugs used in the treatment of COVID-19 and complications of this disease has grown significantly in the global market – there are problems with production due to delays in deliveries.
“This is not a critical situation for the industry as a whole. We have to restructure, place orders earlier, realizing that delivery times will be longer than they were before the pandemic. For the entire time of the pandemic, consumers have not particularly felt a shortage of medicines,” he said.